CDI recurrence rates were significantly lower with high-dose VE303 bacterial consortium versus placebo<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, April 19, 2023 (HealthDay News) — For adults with laboratory-confirmed Clostridioides difficile<\/em> infection (CDI) at high risk for recurrence, high-dose VE303, a defined bacterial consortium of eight strains of commensal Clostridia, prevents recurrent CDI, according to a study published online April 15 in the Journal of the American Medical Association<\/em> to coincide with the 33rd European Congress of Clinical Microbiology & Infectious Diseases, held from April 15 to 18 in Copenhagen, Denmark.<\/p>\n Thomas Louie, M.D., from the University of Calgary and Foothills Medical Centre in Canada, and colleagues examined the efficacy of VE303 in adults at high risk for CDI recurrence in a phase 2 randomized double-blind trial involving 79 participants aged 18 years and older. Participants, who were diagnosed with laboratory-confirmed CDI with one or more prior episodes in the last six months and those with primary CDI at high risk for recurrence, were randomly assigned to high-dose VE303, low-dose VE303, or placebo capsules (30, 27, and 22 participants, respectively), taken orally once daily for 14 days.<\/p>\n The researchers found that for high-dose VE303, low-dose VE303, and placebo, CDI recurrence rates were 13.8, 37.0, and 45.5 percent, respectively, through week 8.<\/p>\n “To our knowledge, this is the first double-blind, placebo-controlled study to demonstrate efficacy with a defined bacterial consortium in any therapeutic indication,” the authors write.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Vedanta Biosciences, which developed VE303.<\/p>\n Abstract\/Full Text<\/a><\/p>\n